Genocea Biosciences Inc. (NASDAQ:GNCA) shares traded down 3.8% during trading on Thursday . The company traded as low as $4.22 and last traded at $4.30, with a volume of 195,023 shares changing hands. The stock had previously closed at $4.47.

A number of research analysts have recently commented on the company. Needham & Company LLC reiterated a “buy” rating and issued a $15.00 price target on shares of Genocea Biosciences in a research note on Friday, April 1st. FBR & Co reiterated a “buy” rating on shares of Genocea Biosciences in a research note on Friday, June 10th. Stifel Nicolaus increased their price target on Genocea Biosciences from $11.00 to $13.00 and gave the company a “buy” rating in a research note on Friday, April 1st. Finally, Zacks Investment Research cut Genocea Biosciences from a “buy” rating to a “hold” rating in a research note on Wednesday, July 6th. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $18.13.

The company’s market capitalization is $122.47 million. The firm’s 50 day moving average price is $4.27 and its 200-day moving average price is $4.31.

Genocea Biosciences (NASDAQ:GNCA) last released its quarterly earnings data on Thursday, May 5th. The company reported ($0.35) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.42) by $0.07. Analysts anticipate that Genocea Biosciences Inc. will post ($1.74) EPS for the current fiscal year.

An institutional investor recently raised its position in Genocea Biosciences stock. AWM Investment Company Inc. raised its position in shares of Genocea Biosciences Inc. (NASDAQ:GNCA) by 45.3% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 715,000 shares of the company’s stock after buying an additional 222,900 shares during the period. AWM Investment Company Inc. owned about 2.54% of Genocea Biosciences worth $3,768,000 as of its most recent filing with the SEC.

Genocea Biosciences, Inc is a biopharmaceutical company. The Company discovers and develops vaccines and immunotherapies. It uses its discovery platform, AnTigen Lead Acquisition System (ATLAS), to design vaccines and immunotherapies that act, in part, through T cell (or cellular) immune responses. The Company operates through business of developing and commercializing vaccines segment.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.